calcium sensitiser

(redirected from calcium sensitizer)

calcium sensitiser

Any of a new class of inotropic agents—e.g., levosimendan—that relax coronary smooth muscle and induce vasodilation by opening ATP-dependent K-channels in vascular smooth muscle. Calcium sensitisers may be useful in managing congestive heart failure.
References in periodicals archive ?
Levosimendan is a calcium sensitizer that works through a unique triple mechanism of action.
Tenax Therapeutics is reportedly focused on its Phase 3 development programme for levosimendan, a calcium sensitizer for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS).
Abstract: Pimobendan is a phosphodiesterase (PDE) inhibitor and calcium sensitizer with inotropic, lusitropic, and rasodilator properties used in the treatment of congestive heart failure.
Perrone SV, Kaplinsky EJ: Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
We found that the calcium sensitizer levosimendan improves the mechanical efficiency of the human diaphragm, suggesting a new, therapeutic approach to improve respiratory muscle function in patients with respiratory failure," said Leo Heunks, M.
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction.
Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function.
Levosimendan, a first-in-class calcium sensitizer, improves cardiac function and symptoms.
Initial data look promising for a calcium sensitizer called levosimendan, but results so far are mixed for a neurohormonal antagonist called tezosentan.
Levosimendan is a new calcium sensitizer and K-ATP channel opener, has emerged as an alternative option of pharmacologic inotropic support in patients with decompensated heart failure.
Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Full browser ?